Effect of Dose and Timing of Preoperative Statins on Mortality After Coronary Artery Bypass Surgery

被引:14
作者
Curtis, Michael
Deng, Yi
Lee, Vei-Vei
Elayda, MacArthur A.
Coselli, Joseph S.
Collard, Charles D.
Pan, Wei
机构
[1] Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA
[2] Texas Heart Inst, Dept Biostat & Epidemiol, Houston, TX 77025 USA
[3] Baylor Coll Med, Dept Cardiovasc Surg, Houston, TX 77030 USA
[4] Texas Heart Inst, Houston, TX 77025 USA
[5] Baylor St Lukes Med Ctr, Texas Heart Inst, Div Cardiovasc Anesthesiol, Houston, TX USA
关键词
ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; CARDIAC-SURGERY; THERAPY; ATORVASTATIN; EVENTS; INTERVENTION; PRAVASTATIN; REDUCTION; WOMEN;
D O I
10.1016/j.athoracsur.2016.12.043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Preoperative statin administration is associated with reduced mortality risk after a coronary artery bypass graft operation. However, the optimal dose and timing are unknown. Methods. We retrospectively reviewed data from 3,025 primary isolated coronary artery bypass graft surgery patients at our institution. Patients were divided into three groups, according to timing of their preoperative statin: 24 hours or less (n = 1,788), 24 to 72 hours (n = 452), or more than 72 hours before operation or no dose (n = 781). We then grouped patients by preoperative dose: no statin (n = 739), 20 mg or less (n = 920), or more than 20 mg (n = 1,284) atorvastatin or equivalent. Primary outcome was 30-day all-cause postoperative mortality. Results. Thirty-day all-cause mortality was significantly lower for patients taking a statin 24 hours or less preoperatively (1.7%) compared with 24 to 72 hours (2.9%), more than 72 hours, or no dose (3.8%). Multivariate analysis of a propensity-matched cohort showed taking statins 24 hours or less preoperatively was associated with reduced 30-day all-cause mortality (odds ratio 0.52, 95% confidence interval: 0.28 to 0.98, p = 0.04) versus more than 24 hours or no dose. For preoperative statin dose, 30-day all-cause mortality was significantly lower when taking 20 mg or less(1.8%) or more than 20 mg atorvastatin or equivalent (2.1%) than when taking none (3.8%). In multivariate analysis of the propensity-matched cohort, more than 20 mg preoperative dose was associated with a 68% reduction of 30-day all-cause mortality (odds ratio 0.32, 95% confidence interval: 0.13 to 0.82, p = 0.02) compared with no preoperative statin. However, a 20 mg or less preoperative dose showed no mortality reduction. Conclusions. Both statin use 24 hours or less preoperatively and preoperative statin dose of more than 20 mg were independently associated with decreased 30-day allcause mortality after coronary artery bypass graft surgery. (C) 2017 by The Society of Thoracic Surgeons
引用
收藏
页码:782 / 789
页数:8
相关论文
共 31 条
[11]   Preoperative statin treatment reduces systemic inflammatory response and myocardial damage in cardiac surgery [J].
Manuel Martinez-Comendador, Jose ;
Rubio Alvarez, Jose ;
Mosquera, Ignacio ;
Sierra, Juan ;
Adrio, Belen ;
Carro, Javier G. ;
Fernandez, Angel ;
Bengochea, Jose .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (06) :998-1005
[12]   Observational study on the beneficial effect of preoperative statins in reducing atrial fibrillation after coronary surgery [J].
Mariscalco, Giovanni ;
Lorusso, Roberto ;
Klersy, Catherine ;
Ferrarese, Sandro ;
Tozzi, Matteo ;
Vanoli, Davide ;
Domenico, Bruno Vito ;
Sala, Andrea .
ANNALS OF THORACIC SURGERY, 2007, 84 (04) :1158-1165
[13]   Perioperative Statin Therapy Is Associated With a Significant and Dose-Dependent Reduction of Adverse Cardiovascular Outcomes After Coronary Artery Bypass Graft Surgery [J].
Ouattara, Alexandre ;
Benhaoua, Hamina ;
Le Manach, Yannick ;
Mabrouk-Zerguini, Nejma ;
Itani, Omar ;
Osman, Amer ;
Landi, Marc ;
Riou, Bruno ;
Coriat, Pierre .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2009, 23 (05) :633-638
[14]   Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery [J].
Pan, W ;
Pintar, T ;
Anton, J ;
Lee, VV ;
Vaughn, WK ;
Collard, CD .
CIRCULATION, 2004, 110 (11) :II45-II49
[15]   Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention - Results of the ARMYDA-ACS randomized trial [J].
Patti, Giuseppe ;
Pasceri, Vincenzo ;
Colonna, Giuseppe ;
Miglionico, Marco ;
Fischetti, Dionigi ;
Sardella, Gennaro ;
Montinaro, Antonio ;
Di Sciascio, Germano .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (12) :1272-1278
[16]   Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery - Results of the ARMYDA-3 (Atorvastatin for reduction of MYocardial dysrhythmia after cardiac surgery) study [J].
Patti, Giuseppe ;
Chello, Massimo ;
Candura, Dario ;
Pasceri, Vincenzo ;
D'Ambrosio, Andrea ;
Covino, Elvio ;
Di Sciascio, Germano .
CIRCULATION, 2006, 114 (14) :1455-1461
[17]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[18]  
Pound EM, 2001, J LIPID RES, V42, P346
[19]   Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein [J].
Ridker, Paul M. ;
Danielson, Eleanor ;
Fonseca, Francisco A. H. ;
Genest, Jacques ;
Gotto, Antonio M., Jr. ;
Kastelein, John J. P. ;
Koenig, Wolfgang ;
Libby, Peter ;
Lorenzatti, Alberto J. ;
MacFadyen, Jean G. ;
Nordestgaard, Borge G. ;
Shepherd, James ;
Willerson, James T. ;
Glynn, Robert J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (21) :2195-2207
[20]   Safety of Perioperative statin use in high-risk patients undergoing major vascular surgery [J].
Schouten, O ;
Kertai, MD ;
Bax, JJ ;
Durazzo, AES ;
Biagini, E ;
Boersma, E ;
van Waning, VH ;
Lameris, TW ;
van Sambeek, MRHM ;
Poldermans, D .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (05) :658-660